Fusion Pharmaceuticals Dividends and Buybacks
Dividend criteria checks 0/6
Fusion Pharmaceuticals does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-7.2%
Buyback Yield
| Total Shareholder Yield | -7.2% |
| Future Dividend Yield | n/a |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
No updates
Recent updates
Fusion Pharmaceuticals' Partnerships Strengthen Long-Term Outlook
Mar 03Health Check: How Prudently Does Fusion Pharmaceuticals (NASDAQ:FUSN) Use Debt?
Jan 30
Fusion Pharmaceuticals initiated at buy at Truist on lead candidate for solid tumors
Sep 16Fusion Pharma doses first patient in phase 1/2 study for solid tumors treatment
Aug 29Will Fusion Pharmaceuticals (NASDAQ:FUSN) Spend Its Cash Wisely?
Aug 10Fusion Pharmaceuticals GAAP EPS of -$0.44 beats by $0.09, revenue of $0.57M beats by $0.46M
Aug 09Fusion Pharma wins FDA nod to start trials for solid tumor candidate
Jun 23We're Not Very Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Rate
Jan 16We're Not Very Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Rate
Aug 28Fusion Pharma trades higher on early-stage data for cancer therapy
Jun 14We're Hopeful That Fusion Pharmaceuticals (NASDAQ:FUSN) Will Use Its Cash Wisely
Apr 05How Much Of Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Do Institutions Own?
Mar 01Who Has Been Buying Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Shares?
Jan 25Here's Why We're Not Too Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Situation
Dec 21Fusion Pharmaceuticals EPS misses by $0.04
Nov 10Fusion Pharma teams up with AstraZeneca in next-gen radiopharmaceuticals for cancer
Nov 02Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if FUSN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if FUSN's dividend payments have been increasing.
Dividend Yield vs Market
| Fusion Pharmaceuticals Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (FUSN) | n/a |
| Market Bottom 25% (US) | 1.4% |
| Market Top 25% (US) | 4.4% |
| Industry Average (Biotechs) | 2.4% |
| Analyst forecast (FUSN) (up to 3 years) | n/a |
Notable Dividend: Unable to evaluate FUSN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate FUSN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate FUSN's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as FUSN has not reported any payouts.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/06/06 07:00 |
| End of Day Share Price | 2024/06/04 00:00 |
| Earnings | 2024/03/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Fusion Pharmaceuticals Inc. is covered by 14 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Martin | Bloom Burton & Co. |
| Justin Walsh | B. Riley Securities, Inc. |
| Brian Kemp Dolliver | Brookline Capital Markets |